Imaging prostate cancer with a new radiotracer
Official title: 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
Run by First Affiliated Hospital of Chongqing Medical University · NCT06419348 · Data updated 2026-11-12
This study is testing a new imaging agent to see if it can help identify prostate cancer in patients whose tumors have a specific marker called PSMA.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | First Affiliated Hospital of Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Status | Recruiting |
| Started | May 20, 2024 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | June 4, 2025 |
| Trial ID | NCT06419348 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with suspected or diagnosed prostate cancer that shows PSMA positive expression.
✕Probably not a fit
Patients with PSMA negative expression or serious medical conditions that may interfere with the study will not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the safety and effectiveness of a new radiotracer, 99mTc-QULIC-5-P1, for SPECT imaging in patients with prostate cancer that expresses PSMA. The study aims to determine how well this imaging agent can identify lesions associated with PSMA positive prostate cancer. Participants will undergo imaging procedures to assess the biodistribution of the radiotracer and its potential usefulness in diagnosing prostate cancer. The trial is designed for early-phase evaluation, focusing on the initial safety and imaging capabilities of the agent.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of prostate cancer diagnosis and improve patient management.
How similar studies have gone: While this specific approach is novel, similar imaging techniques targeting PSMA have shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc). Exclusion Criteria: 1. Patients with PSMA negative expression. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Where it's running
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China Recruiting
Study contacts
- Study coordinator: Xiaoyang Zhang, PhD
- Email: zhangxy@mail.bnu.edu.cn
- Phone: 023-89011755
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing heart imaging techniques for coronary artery disease
This study is testing if a new heart imaging method can better identify problems in patients suspected of having coronary artery disease compared to a traditional imaging technique.
-
Imaging with 68Ga-PSFA in patients with specific cancer markers
This study is testing a new imaging agent to see if it can help find cancer spots in patients with certain cancer markers.
-
Registry assessing PSMA PET outcomes in prostate cancer
This study is testing if PSMA PET imaging can help doctors better understand the outcomes for men with prostate cancer compared to traditional methods.
-
Evaluating new methods for detecting exercise-induced heart issues
This study is testing new ways to spot heart problems that can happen during exercise to see if they work better than the usual methods and can help predict long-term heart risks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.